Biocon’s arm divests BFI Non-Core Business to Eris Lifesciences

10 Nov 2023 Evaluate

Biocon’s subsidiary -- Biocon Biologics has divested the businesses in relation to its non-core branded formulations in India, comprising, inter alia, of generic dermatology and nephrology small molecule formulations (BFI Non-Core Business) to Eris Lifesciences on a ‘slump sale’ basis. Consideration received from such sale/disposal is Rs 366 crore including working capital adjustments. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

308.65 -2.15 (-0.69%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.